Renal Acute MI Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01580566|
Recruitment Status : Recruiting
First Posted : April 19, 2012
Last Update Posted : April 11, 2017
The purpose of this study is to determine if a sizable myocardial infarction (heart attack) results in negative changes to renal structure and function (i.e. has a negative impact on the kidneys).
To determine if the renal response to a myocardial infarction is a predictor of the patients future health.
|Condition or disease|
|Myocardial Infarction Kidney Function|
|Study Type :||Observational|
|Estimated Enrollment :||160 participants|
|Official Title:||Renal Structural, Functional and Cytokine Responses to Acute Myocardial Injury in Man|
|Study Start Date :||March 2012|
|Estimated Primary Completion Date :||June 2018|
|Estimated Study Completion Date :||December 2018|
Group 1 - Control
Non-Q wave MI subjects with normal cardiac and renal function (defined as eGFR >60ml/min) not undergoing a cardiac procedure involving contrast will serve as "control" for renal injury subjects.
Group 2 - stable CAD or non-Q wave MI
Patients undergoing coronary angiography +/- PCI for stable CAD or non-Q wave MI with normal cardiac and renal function (defined as eGFR >60ml/min) will control for the contrast STEMI patients are likely to receive as part of their post-MI management
Group 3 - Acute STEMI without chronic kidney disease
Acute STEMI patients (n=40), without chronic kidney disease (defined as eGFR ≥60ml/min).
Group 4 - Acute STEMI with kidney disease
Acute STEMI patients (n=40), with evidence of background chronic kidney disease (eGFR <60ml/min).
- changes in renal function and structure [ Time Frame: Baseline, discharge, 1 month, 6 months and 12 months ]
- renal response to myocardial infarction [ Time Frame: baseline, discharge, 1 month, 6 months and 12 months ]
Biospecimen Retention: Samples With DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01580566
|Contact: Henry Krum, MBBS FRACP PhD||+613 9903 email@example.com|
|Melbourne, Victoria, Australia, 3004|
|Contact: Henry Krum, MBBS FRACP PhD +613 9903 0042 firstname.lastname@example.org|
|Principal Investigator: Henry Krum, MBBS FRACP PhD|
|Principal Investigator:||Henry Krum, MBBS FRACP PhD||Alfred Hospital/Monash.University|
|Principal Investigator:||Henry Krum, MBBS FRACP PhD||Alfred Hospital/Monash University|